At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2015.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.